Orbimed Advisors Llc Buys Humana Inc, Cigna Corp, Principia Biopharma Inc, Sells Alnylam Pharmaceuticals Inc, Amicus Therapeutics Inc, Biogen Inc

• New Purchases: PRNB, MOH, PTCT, CRNX, CNC, BHC, ARVN, SPPI, AET, ACIU,
• Added Positions: HUM, CI, SRPT, MYL, MD, TMO, EW, EXEL, ASMB, UNH,
• Reduced Positions: FOLD, BIIB, SEM, MRK, BSX, A, AERI, JNJ, LOXO, VRTX,
• Sold Out: ALNY, ACAD, SHPG, UHS, INCY, LPNT, MGLN, STDY, KTWO, AMED,

For the details of ORBIMED ADVISORS LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=ORBIMED+ADVISORS+LLC

1. Alexion Pharmaceuticals Inc (ALXN) - 2,881,103 shares, 4.86% of the total portfolio. Shares reduced by 7.79%
2. Tricida Inc (TCDA) - 10,889,280 shares, 4.04% of the total portfolio.
3. Biogen Inc (BIIB) - 910,300 shares, 3.9% of the total portfolio. Shares reduced by 22.06%
4. Vertex Pharmaceuticals Inc (VRTX) - 1,600,500 shares, 3.74% of the total portfolio. Shares reduced by 10.72%
5. Boston Scientific Corp (BSX) - 7,863,995 shares, 3.67% of the total portfolio. Shares reduced by 17.87%

Orbimed Advisors Llc initiated holding in Principia Biopharma Inc. The purchase prices were between $26.04 and $32.65, with an estimated average price of $28.22. The stock is now traded at around $29.82. The impact to a portfolio due to this purchase was 0.92%. The holding were 2,605,713 shares as of 2018-09-30.

Orbimed Advisors Llc initiated holding in Molina Healthcare Inc. The purchase prices were between $98.71 and $152.72, with an estimated average price of $127.37. The stock is now traded at around $142.79. The impact to a portfolio due to this purchase was 0.88%. The holding were 488,781 shares as of 2018-09-30.

Orbimed Advisors Llc initiated holding in PTC Therapeutics Inc. The purchase prices were between $33.9 and $47.77, with an estimated average price of $41.27. The stock is now traded at around $33.76. The impact to a portfolio due to this purchase was 0.73%. The holding were 1,275,000 shares as of 2018-09-30.

Orbimed Advisors Llc initiated holding in Crinetics Pharmaceuticals Inc. The purchase prices were between $22.66 and $36.8, with an estimated average price of $29.7. The stock is now traded at around $33.81. The impact to a portfolio due to this purchase was 0.67%. The holding were 1,914,282 shares as of 2018-09-30.

Orbimed Advisors Llc initiated holding in Centene Corp. The purchase prices were between $124.06 and $146.88, with an estimated average price of $138.85. The stock is now traded at around $132.87. The impact to a portfolio due to this purchase was 0.59%. The holding were 337,400 shares as of 2018-09-30.

Orbimed Advisors Llc initiated holding in Bausch Health Companies Inc. The purchase prices were between $20.64 and $25.67, with an estimated average price of $22.9. The stock is now traded at around $23.65. The impact to a portfolio due to this purchase was 0.59%. The holding were 1,903,900 shares as of 2018-09-30.

Orbimed Advisors Llc added to a holding in Humana Inc by 441.32%. The purchase prices were between $298.8 and $340.61, with an estimated average price of $324.9. The stock is now traded at around $312.50. The impact to a portfolio due to this purchase was 1.31%. The holding were 393,000 shares as of 2018-09-30.

Orbimed Advisors Llc added to a holding in Cigna Corp by 195.11%. The purchase prices were between $169.03 and $208.25, with an estimated average price of $185.38. The stock is now traded at around $211.95. The impact to a portfolio due to this purchase was 1.06%. The holding were 633,900 shares as of 2018-09-30.

Orbimed Advisors Llc added to a holding in Sarepta Therapeutics Inc by 88.78%. The purchase prices were between $115.31 and $161.51, with an estimated average price of $136.71. The stock is now traded at around $122.02. The impact to a portfolio due to this purchase was 0.79%. The holding were 854,400 shares as of 2018-09-30.

Orbimed Advisors Llc added to a holding in Mylan NV by 29.08%. The purchase prices were between $35.53 and $39.48, with an estimated average price of $37.54. The stock is now traded at around $30.04. The impact to a portfolio due to this purchase was 0.48%. The holding were 4,779,600 shares as of 2018-09-30.

Orbimed Advisors Llc added to a holding in Mednax Inc by 70.33%. The purchase prices were between $42.76 and $48.58, with an estimated average price of $45.91. The stock is now traded at around $37.53. The impact to a portfolio due to this purchase was 0.34%. The holding were 1,469,300 shares as of 2018-09-30.

Orbimed Advisors Llc added to a holding in Exelixis Inc by 66.66%. The purchase prices were between $15.87 and $22.4, with an estimated average price of $19.52. The stock is now traded at around $21.29. The impact to a portfolio due to this purchase was 0.24%. The holding were 2,801,900 shares as of 2018-09-30.

Orbimed Advisors Llc sold out a holding in Alnylam Pharmaceuticals Inc. The sale prices were between $87.52 and $122.67, with an estimated average price of $100.59.

Orbimed Advisors Llc sold out a holding in ACADIA Pharmaceuticals Inc. The sale prices were between $13.03 and $21.81, with an estimated average price of $15.72.

Orbimed Advisors Llc sold out a holding in Shire PLC. The sale prices were between $166.29 and $181.27, with an estimated average price of $173.02.

Orbimed Advisors Llc sold out a holding in Universal Health Services Inc. The sale prices were between $110.98 and $130.16, with an estimated average price of $122.74.

Orbimed Advisors Llc sold out a holding in Incyte Corp. The sale prices were between $61.75 and $74.23, with an estimated average price of $68.71.

Orbimed Advisors Llc sold out a holding in LifePoint Health Inc. The sale prices were between $47.45 and $64.9, with an estimated average price of $60.93.

Orbimed Advisors Llc reduced to a holding in Amicus Therapeutics Inc by 75.07%. The sale prices were between $11.6 and $16.54, with an estimated average price of $14.01. The stock is now traded at around $10.52. The impact to a portfolio due to this sale was -1%. Orbimed Advisors Llc still held 1,763,277 shares as of 2018-09-30.

Orbimed Advisors Llc reduced to a holding in Biogen Inc by 22.06%. The sale prices were between $293.51 and $383.83, with an estimated average price of $343.66. The stock is now traded at around $320.14. The impact to a portfolio due to this sale was -0.9%. Orbimed Advisors Llc still held 910,300 shares as of 2018-09-30.

Orbimed Advisors Llc reduced to a holding in Select Medical Holdings Corp by 79.61%. The sale prices were between $18 and $21.6, with an estimated average price of $19.22. The stock is now traded at around $17.94. The impact to a portfolio due to this sale was -0.88%. Orbimed Advisors Llc still held 1,034,711 shares as of 2018-09-30.

Orbimed Advisors Llc reduced to a holding in Merck & Co Inc by 24.26%. The sale prices were between $60.46 and $71.1, with an estimated average price of $66.77. The stock is now traded at around $79.01. The impact to a portfolio due to this sale was -0.83%. Orbimed Advisors Llc still held 3,544,400 shares as of 2018-09-30.

Orbimed Advisors Llc reduced to a holding in Agilent Technologies Inc by 42.44%. The sale prices were between $61.25 and $71.13, with an estimated average price of $66.18. The stock is now traded at around $71.14. The impact to a portfolio due to this sale was -0.59%. Orbimed Advisors Llc still held 1,085,100 shares as of 2018-09-30.

Orbimed Advisors Llc reduced to a holding in Aerie Pharmaceuticals Inc by 35.26%. The sale prices were between $56.15 and $73.9, with an estimated average price of $64.23. The stock is now traded at around $39.01. The impact to a portfolio due to this sale was -0.54%. Orbimed Advisors Llc still held 1,219,830 shares as of 2018-09-30.